Adrien Monard
143-147 Boulevard Anatole France
Saint-denis-de-palin, 93285, France
Saint-denis-de-palin, 93285, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Clinical outcome of advanced or recurrent endometrial carcinoma treated with chemotherapy: a French observational retrospective cohort: the ENDOVIE study.
Journal: BMJ open
Published: September 04, 2025
PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort study.
Journal: The Lancet regional health. Europe
Published: June 11, 2025
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric Cancer in a Real-World Setting: A Nationwide Cohort Study.
Journal: Clinical and translational gastroenterology
Published: July 08, 2024
Clinical relevance of reports on early access programs for checkpoint inhibitors in cancer patients: a French retrospective nationwide cohort study.
Journal: ESMO open
Published: June 07, 2024
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab.
Journal: Cancer chemotherapy and pharmacology
Published: April 20, 2023
Early access to innovative drugs, ethical impacts
Journal: La Revue du praticien
Published: December 13, 2022
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.
Journal: International journal of cancer
Published: November 16, 2021
Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 12, 2021
Response to the letter: Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 08, 2021
Administrative delays of temporary recommendation for use: Impact on access to innovation in melanoma
Journal: Bulletin du cancer
Published: June 23, 2021
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 25, 2020
Evaluation of Clinical Trials in Onco-haematology: A New Method Based on Risk Analysis and Multidisciplinarity.
Journal: Therapeutic innovation & regulatory science
Published: June 29, 2020
Last Updated: 09/26/2026